1st Circ. Upholds Biogen's Win In Drug Sales Forecast Suit
The First Circuit on Friday backed the dismissal of a proposed securities class action against drugmaker Biogen Inc., saying investors had failed to plead specific facts that prove the company intentionally...To view the full article, register now.
Already a subscriber? Click here to view full article